giovanni porta
University of Insubria
Varese, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
University of Insubria
Varese, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
INSERM U1021 Signalisation Normale et Pathologique de l'embryon aux Thérapies Innovantes des Cancers
Orsay, France
Review Editor
Cancer Molecular Targets and Therapeutics
Thermo Fisher Scientific (United States)
San Jose, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Cyprus University of Technology
Limassol, Cyprus
Review Editor
Cancer Molecular Targets and Therapeutics
University of Kentucky
Lexington, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Department of Hematology, Fifth Medical Center of the PLA General Hospital
Beijing, China
Review Editor
Cancer Molecular Targets and Therapeutics
Nanjing University of Chinese Medicine
Nanjing, China
Review Editor
Cancer Molecular Targets and Therapeutics
National and Kapodistrian University of Athens
Athens, Greece
Review Editor
Cancer Molecular Targets and Therapeutics
Department of Biology and Biotechnology Lazzaro Spallanzani, University of Pavia
Pavia, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
Tempus Labs (United States)
Chicago, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Khalifa University
Abu Dhabi, United Arab Emirates
Review Editor
Cancer Molecular Targets and Therapeutics
University of Oklahoma Health Sciences Center
Oklahoma City, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Halda Therapeutics
New Haven, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Mayo Clinic
Rochester, United States
Review Editor
Cancer Molecular Targets and Therapeutics
Sapienza University of Rome
Rome, Italy
Review Editor
Cancer Molecular Targets and Therapeutics
University of Kentucky
Lexington, United States
Review Editor
Cancer Molecular Targets and Therapeutics